Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Ole Weiss Bjerrum"'
Autor:
Lasse Kjær, Ole Weiss Bjerrum, Mads Thomassen, Caroline Hasselbalch Riley, Torben A Kruse, Thomas Stauffer Larsen, Vibe Skov, Hans Carl Hasselbalch
Publikováno v:
Skov, V, Riley, C, Thomassen, M, Kjaer, L, Larsen, T S, Bjerrum, O W, Kruse, T A & Hasselbalch, H C 2018, ' Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN-Alfa Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+Mobilisation ', Blood, vol. 132, no. Suppl. 1 . https://doi.org/10.1182/blood-2018-99-112109
Skov, V, Riley, C H, Thomassen, M, Kjær, L, Larsen, T S, Weiss Bjerrum, O, Kruse, T A & Hasselbalch, H C 2018, ' Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN-Alfa Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation. ', Blood, vol. 126, no. 23 .
Skov, V, Riley, C H, Thomassen, M, Kjær, L, Larsen, T S, Weiss Bjerrum, O, Kruse, T A & Hasselbalch, H C 2018, ' Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN-Alfa Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation. ', American Society of Hematology: 60th Annual Meeting (ASH), San Diego, USA, 29/11/2018-04/12/2018 .
Skov, V, Riley, C H, Thomassen, M, Kjær, L, Larsen, T S, Weiss Bjerrum, O, Kruse, T A & Hasselbalch, H C 2018, ' Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN-Alfa Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation. ', Blood, vol. 126, no. 23 .
Skov, V, Riley, C H, Thomassen, M, Kjær, L, Larsen, T S, Weiss Bjerrum, O, Kruse, T A & Hasselbalch, H C 2018, ' Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN-Alfa Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation. ', American Society of Hematology: 60th Annual Meeting (ASH), San Diego, USA, 29/11/2018-04/12/2018 .
Introduction: The Philadelphia-negative myeloproliferative neoplasms are associated with chronic inflammation and accumulation of reactive oxygen species (ROS). Whole blood transcriptional profiling studies have most recently identified deregulation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03ffe7edb30e49edf92912152b099033
https://portal.findresearcher.sdu.dk/da/publications/1f7d3b31-7070-45cb-96a8-95a5f315ba71
https://portal.findresearcher.sdu.dk/da/publications/1f7d3b31-7070-45cb-96a8-95a5f315ba71
Publikováno v:
ISBT Science Series. 8:114-118
The literature contains little on the prevalence and causes of high predonation haemoglobin levels among blood donors. This study aimed to characterize and develop an algorithm to manage would-be donors with polycythaemia. Between November 2009 and N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c660e3a05b9fbe1960e67564ca18907d
https://doi.org/10.1111/voxs.12041
https://doi.org/10.1111/voxs.12041
Autor:
S, Mustjoki, J, Richter, G, Barbany, H, Ehrencrona, T, Fioretos, T, Gedde-Dahl, B T, Gjertsen, R, Hovland, S, Hernesniemi, D, Josefsen, P, Koskenvesa, I, Dybedal, B, Markevärn, T, Olofsson, U, Olsson-Strömberg, K, Rapakko, S, Thunberg, L, Stenke, B, Simonsson, K, Porkka, H, Hjorth-Hansen, Ole Weiss, Bjerrum
Publikováno v:
Leukemia. 27:1520-1526
Chronic myeloid leukemia (CML) stem cells appear resistant to tyrosine kinase inhibitors (TKIs) in vitro, but their impact and drug sensitivity in vivo has not been systematically assessed. We prospectively analyzed the proportion of Philadelphia chr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41db6ea12ba34d0bf7654cf2c4e7ecab
https://doi.org/10.1038/leu.2013.19
https://doi.org/10.1038/leu.2013.19
Autor:
Anders Själander, Johan Lanng Nielsen, Henrik Hjorth-Hansen, Satu Mustjoki, Kari Remes, Hans Ehrencrona, Ole Weiss Bjerrum, Anders Almqvist, Mats Björeman, Berit Markevärn, Fredrik Sandin, Franz Gruber, Kristina Myhr-Eriksson, Claes Malm, Max Flogegard, Arnon Nagler, V Kairisto, Ulla Strömberg, Perttu Koskenvesa, Anders Lindblom, Kimmo Porkka, Karin Olsson, Marjatta Sinisalo, Jesper Stentoft, Tobias Gedde-Dahl, Bengt Simonsson, Lotta Ohm, Anu Räsänen
Publikováno v:
Simonsson, B, Gedde-Dahl, T, Markevärn, B, Remes, K, Stentoft, J, Almqvist, A, Björeman, M, Flogegård, M, Koskenvesa, P, Lindblom, A, Malm, C, Mustjoki, S, Myhr-Eriksson, K, Ohm, L, Räsänen, A, Sinisalo, M, Själander, A, Strömberg, U, Bjerrum, O W, Ehrencrona, H, Gruber, F, Kairisto, V, Olsson, K, Sandin, F, Nagler, A, Nielsen, J L, Hjorth-Hansen, H, Porkka, K & Nordic CML Study Group 2011, ' Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low-or intermediate-risk chronic myeloid leukemia ', Ironic Blood, vol. 118, no. 12, pp. 3228-35 . https://doi.org/10.1182/blood-2011-02-336685
Biologic and clinical observations suggest that combining imatinib with IFN-α may improve treatment outcome in chronic myeloid leukemia (CML). We randomized newly diagnosed chronic-phase CML patients with a low or intermediate Sokal risk score and i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9674851dfcdb18ca880ccd2a0c5a7e59
https://doi.org/10.1182/blood-2011-02-336685
https://doi.org/10.1182/blood-2011-02-336685
Autor:
Bjarne Jensen, Henrik Birgens, Claudia Schöllkopf, Bjarne Egelund Christensen, Lars Kjeldsen, Ellen Birkerod Taaning, B. Pedersen, Tobias Wirenfeldt Klausen, Johan Lanng Nielsen, Hans Torben Mourits-Andersen, Ole Weiss Bjerrum
Publikováno v:
Leukemia & Lymphoma. 47:253-260
Chronic cold agglutinin disease (CAD) is an acquired autoimmune hemolytic anemia. Previous therapeutic modalities, including alkylating cytostatics, interferon and prednisolone, have been disappointing. However, several case reports and small-scaled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01f582eb637e7929915093718a67fde2
https://doi.org/10.1080/10428190500286481
https://doi.org/10.1080/10428190500286481
Autor:
Hans Carl Hasselbalch, Henrik Birgens, Elisabeth Ralfkiaer, Per Boye Hansen, B A Jensen, Marianne Hamilton Therkildsen, Nielsaage Tøffner Clausen, Ole Weiss Bjerrum
Publikováno v:
American Journal of Hematology. 74:238-242
Imatinib mesylate targets the adenosine triphosphate (ATP)-binding sites of the protein tyrosine kinase domains associated with Bcr-abl, the platelet-derived growth factor (PDGF) and c-kit. In idiopathic myelofibrosis (IMF) PDGF is considered to be o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01ca5a0bf59ae18f2930dd2b9068c50c
https://doi.org/10.1002/ajh.10431
https://doi.org/10.1002/ajh.10431
Autor:
Luciano Levato, Ugur Ozbek, Elisabetta Abruzzese, Henrik Hjorth-Hansen, Fausto Castagnetti, Giovanna Rege-Cambrin, Nicoletta Testoni, Francesca Palandri, Domenico Russo, Giovanni Martinelli, Michele Baccarani, Johann Lanng Nielsen, Veli Kairisto, Giuseppe Saglio, Giuliana Alimena, Fabrizio Pane, Fausto Palmieri, Arnon Nagler, Gianantonio Rosti, Bengt Simonsson, Ibrahim C. Haznedaroglu, Kimmo Porkka, Giorgina Specchia, Ole Weiss-Bjerrum, Hans Ehrencrona
Publikováno v:
Baccarani, M, Rosti, G, Castagnetti, F, Haznedaroglu, I, Porkka, K, Abruzzese, E, Alimena, G, Ehrencrona, H, Hjorth-Hansen, H, Kairisto, V, Levato, L, Martinelli, G, Nagler, A, Lanng Nielsen, J, Ozbek, U, Palandri, F, Palmieri, F, Pane, F, Rege-Cambrin, G, Russo, D, Specchia, G, Testoni, N, Weiss-Bjerrum, O, Saglio, G & Simonsson, B 2009, ' Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study ', Blood, vol. 113, no. 19, pp. 4497-504 . https://doi.org/10.1182/blood-2008-12-191254
Imatinib mesylate (IM), 400 mg daily, is the standard treatment of Philadelphia-positive (Ph+) chronic myeloid leukemia (CML). Preclinical data and results of single-arm studies raised the suggestion that better results could be achieved with a highe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dba6282f00c96c29bdbe01db6cb6645d
http://hdl.handle.net/11379/531286
http://hdl.handle.net/11379/531286
Autor:
Ole Weiss Bjerrum, Leif Stenke, Claes Malm, Tobias Gedde Dahl, Perttu Koskenvesa, Ali Moshfegh, Waleed Majeed, Randi Hovland, Ingunn Dybedal, Kimmo Porkka, Ulla Olsson Strömberg, Dag Josefsen, Henrik Hjorth Hansen, Sari E. Jalkanen, Lotta Ohm, Kirsi Latvala, Satu Mustjoki, Bengt Simonsson, Kari Remes, Johan Richter, Jesper Stentoft, Merja Suominen, Gisela Barbany, Tor Olofsson, Berit Markevärn, Thoas Fioretos, Carin Lassen, Katrin Rapakko, Bjørn Tore Gjertsen, Sara Thunberg
Publikováno v:
Blood. 116:667-667
Abstract 667 Background: Targeted tyrosine kinase inhibitor (TKI) therapy efficiently induces rapid hematologic and cytogenetic responses in most CML patients. In vitro studies have suggested that CML stem cells are resistant to TKIs and therefore th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69409e0e6d9161b9062f56b8e2915037
https://doi.org/10.1182/blood.v116.21.667.667
https://doi.org/10.1182/blood.v116.21.667.667
Autor:
Anders Lindblom, Satu Mustjoki, Veli Kairisto, Anders Själander, Johan Lanng Nielsen, Henrik Hjorth-Hansen, Kristina Myhr-Eriksson, Ulla Olsson Strömberg, Ole Weiss Bjerrum, Anu Räsänen, Karin Rn Olsson, Mats Björeman, Heikki Hallman, Claes Malm, Kimmo Porkka, Kari Remes, Risto Sippola, Max Flogegard, Berit Markevärn, Franz Gruber, Anders Almqvist, Perttu Koskenvesa, Hans Ehrencrona, Jesper Stentoft, Marjatta Sinisalo, Arnon Nagler, Tobias Gedde-Dahl, Bengt Simonsson
Publikováno v:
Blood. 114:3280-3280
Abstract 3280 Poster Board III-1 Background: Imatinib mesylate (IM) 400 mg once daily (OD) is the current standard first-line therapy for CML. Several biological and clinical observations suggest that combining IM with interferon alpha (IFNa) may imp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aff8e0437fc5ae32f65abcaae3572ce6
https://doi.org/10.1182/blood.v114.22.3280.3280
https://doi.org/10.1182/blood.v114.22.3280.3280
Autor:
Satu Maarit Mustjoki, Johan Richter, Gisela Barbany, Ingunn Dybedal, Thoas Fioretos, Tobias Gedde-Dahl, Gjertsen, Bjorn T., Randi Hovland, Sari Jalkanen, Dag Josefsen, Perttu Koskenvesa, Carin Lassen, Kirsi Latvala, Waleed Majeed, Claes Malm, Berit Markevarn, Ali Moshfegh, Lotta Ohm, Tor Olofsson, Ulla Olsson-Stromberg, Katrin Rapakko, Kari Remes, Jesper Stentoft, Leif Stenke, Merja Suominen, Sara Thunberg, Ole Weiss Bjerrum, Bengt Simonsson, Kimmo Porkka, Henrik Hjorth-Hansen
Publikováno v:
ResearcherID
University of Helsinki
University of Helsinki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::3cd5a012783a36b36f958acd7f5e9675
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000289662200668&KeyUID=WOS:000289662200668
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000289662200668&KeyUID=WOS:000289662200668